Table 1.
Patient characteristics
| Total | |
|---|---|
| (n = 302) | |
| Gender | |
| Female | 145 (48%) |
| Male | 157 (52%) |
| Age | |
| Median, range | 60 (26–86) |
| Metastatic sites | |
| ≤2 | 111 (37%) |
| >2 | 190 (63%) |
| Missing | 1 (0%) |
| Albumin | |
| ≥35 g/L | 129 (43%) |
| <35 g/L | 168 (56%) |
| Missing | 5 (2%) |
| LDH | |
| >ULN | 196 (65%) |
| ≤ULN | 104 (34%) |
| Missing | 2 (1%) |
| RMH score | |
| 0–1 | 97 (32%) |
| 2–3 | 200 (66%) |
| Missing | 5 (2%) |
| Number of prior treatment regimens | |
| Median, range | 3 (1–11) |
| Performance status (ECOG) | |
| 0 | 99 (33%) |
| 1 | 200 (66%) |
| 2 | 3* (1%) |
*Patients declining in performance status from inclusion to the time of biopsy